Détail du document
Identifiant

doi:10.1186/s12866-023-03114-2...

Auteur
Kim, Hyeoungeun Han, Chi-Young Eun, Su-Hyeon Kim, Min-Goo Im, A-Rang Lee, Byeonghun
Langue
en
Editeur

BioMed Central

Catégorie

Mycology

Année

2023

Date de référencement

29/11/2023

Mots clés
... antimicrobial biofilm ... dental caries oral health disease dental id23029 mutans
Métrique

Résumé

Background Dental caries is a chronic oral disease caused by microbial infections, which result in erosion of the dental enamel and cause irreversible damage.

Therefore, proper disease management techniques and the creation of an environment that prevents intraoral growth and biofilm formation of Streptococcus mutans in the early stages, are crucial to prevent the potential progression of dental plaque to disease.

Here, we aimed to investigate antimicrobial and antibiofilm effects of the Bacillus velezensis ID-A01 supernatant (ID23029) against S. mutans , and its inhibitory effects on acidogenesis.

Results A killing kinetics assay showed a peak lethality percentage of 94.5% after 6 h of exposure to ID23029.

In sucrose-exposed conditions, ID23029 inhibited lactic acid formation, preventing the pH from falling below the threshold for enamel demineralization, and inhibited up to 96.6% of biofilm formation.

This effect was maintained in the presence of lysozyme.

Furthermore, ID23029 retained up to 92% lethality, even at an intraoral concentration at which lysozyme is ineffective against S. mutans .

Conclusions This study demonstrates the potential of the B. velezensis ID-A01 supernatant for the prevention and treatment of dental caries.

Its eventual use in dental practice is encouraged, although further studies are required to confirm its beneficial effects.

Kim, Hyeoungeun,Han, Chi-Young,Eun, Su-Hyeon,Kim, Min-Goo,Im, A-Rang,Lee, Byeonghun, 2023, Inhibitory effects of Bacillus velezensis ID-A01 supernatant against Streptococcus mutans, BioMed Central

Document

Ouvrir

Partager

Source

Articles recommandés par ES/IODE IA

Gene expression profiles in clinically T1-2N0 ER+HER2− breast cancer patients treated with breast-conserving therapy: their added value in case sentinel lymph node biopsy is not performed
breast cancer sentinel lymph node biopsy gene expression profile adjuvant chemotherapy gep treated status guideline-2020 outcome patients cancer chemotherapy breast predict